COVID-19 acute respiratory distress syndrome: can iloprost have a role for the treatment?
Open Access
- 1 January 2021
- journal article
- research article
- Published by Elsevier in Respiratory Medicine Case Reports
- Vol. 32, 101358
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- The acute respiratory distress syndromeJournal of Clinical Investigation, 2012
- Protective Role of Cyclooxygenase (COX)-2 in Experimental Lung Injury: Evidence of a Lipoxin A4-Mediated EffectJournal of Surgical Research, 2012
- Iloprost modulates the immune response in systemic sclerosisBMC Immunology, 2010
- A prostacyclin analogue, iloprost, protects from bleomycin-induced pulmonary fibrosis in miceRespiratory Research, 2010
- Rap1 mediates protective effects of iloprost against ventilator-induced lung injuryJournal of Applied Physiology, 2009
- Signaling through the Prostaglandin I2Receptor IP Protects against Respiratory Syncytial Virus-Induced IllnessJournal of Virology, 2004
- Effects of inhaled nitric oxide in patients with acute respiratory distress syndromeCritical Care Medicine, 1998
- INHIBITION OF TUMOUR NECROSIS FACTOR PRODUCTION IN ENDOTOXIN-STIMULATED HUMAN MONONUCLEAR LEUKOCYTES BY THE PROSTACYCLIN ANALOGUE ILOPROST: CELLULAR MECHANISMSCytokine, 1997
- Aerosolized Surfactant in Adults with Sepsis-Induced Acute Respiratory Distress SyndromeNew England Journal of Medicine, 1996
- Iloprost attenuates trauma-related pulmonary sequestration of leucocytes and plateletsProstaglandins, Leukotrienes and Essential Fatty Acids, 1994